68Ga DOTATATE PET/CT Uptake in Spinal Lesions and MRI Correlation on a Patient With Neuroendocrine Tumor

Klinaki, Ifigeneia; Al-Nahhas, Adil; Soneji, Neil; Win, Zarni

doi:10.1097/rlu.0b013e31827a2325

Cited by 40 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other ligand-targeted radioimaging agents in human clinical trials include somatostatin analogues that are linked to radionuclide-chelating agents, such as edotreotide (DOTATOC), DOTATATE (tetraazacycl ododecane tetraacetic acid-octreotate; NCT01873248 and NCT01967537) and DOTANOC (DOTA-(tyrosine 3)-octreotide; NCT01747096) (FIGS 6,7; TABLE 2), which are being used to image neuroendocrine tumours [188][189][190][191] . SSTR2-targeted radiotherapeutics that use lutetium-177 and yttrium-90 are also currently under evaluation 192,193 .…”

Section: Ligand-targeted Imaging Agentsmentioning

confidence: 99%

Principles in the design of ligand-targeted cancer therapeutics and imaging agents

Srinivasarao

Galliford

Low

2015

Nat Rev Drug Discov

566

502

View full text Add to dashboard Cite

Most cancer drugs are designed to interfere with one or more events in cell proliferation or survival. As healthy cells may also need to proliferate and avoid apoptosis, anticancer agents can be toxic to such cells. To minimize these toxicities, strategies have been developed wherein the therapeutic agent is targeted to tumour cells through conjugation to a tumour-cell-specific small-molecule ligand, thereby reducing delivery to normal cells and the associated collateral toxicity. This Review describes the major principles in the design of ligand-targeted drugs and provides an overview of ligand-drug conjugates and ligand-imaging-agent conjugates that are currently in development.

show abstract

Section: Ligand-targeted Imaging Agentsmentioning

confidence: 99%

Principles in the design of ligand-targeted cancer therapeutics and imaging agents

Srinivasarao

Galliford

Low

2015

Nat Rev Drug Discov

566

502

View full text Add to dashboard Cite

show abstract

“…Somatostatin receptors are expressed by both normal pituitary gland and pituitary tumor. Novel 68 Ga-labeled somatostatin analogs, such as 68 Ga-DOTATATE, are now finding increasing clinical application (9)(10)(11)(12)(13)(14). Previously we reported that 68 Ga-DOTATATE in general had a higher uptake in the remaining pituitary tissue than in the recurrent or residual adenoma.…”

Section: Introductionmentioning

confidence: 99%

PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study

et al. 2017

View full text Add to dashboard Cite

Ga-DOTATATE PET/MR within one week. Finally, 27 patients underwent transsphenoidal adenomectomy within two weeks, 3 patients underwent sella region radiotherapy, 1 patient underwent somatostatin therapy, and the other 6 patients had a clinical follow-up. The image characteristics and uptake levels were correlated with the surgical findings and pathological results. Receiver-operating-characteristic (ROC) curve analysis was performed to determine an optimal cutoff pituitary to differentiate pituitary adenoma from normal pituitary tissue. The area under the ROC curve was calculated to compare the diagnostic performance. Results:The PET/MR images were in diagnostic quality without obvious image artifacts. The high contrast of PET imaging provided complementary information to the fine anatomy display of MRI.Increased 18 F-FDG uptake was clearly observed in the all patients, whereas enhanced MRI enhanced MRI using 0.05 mmol/kg Gadopentetate dimeglumine had suspicious findings only in 47% primary and 39% recurrent PAs patients, which were 37% and 50%, respectively when using 0.1 mmol/kg Gadopentetate dimeglumine. The maximum standardized uptake values (SUVmax) of 18 F-FDG activity (6.8 ± 3.7) in 16 primary pituitary adenomas who underwent transsphenoidal adenomectomy, was significantly higher than that of the rest of the normal pituitary gland (3.2 ± 1.1, P < 0.01). The adenoma showed moderate 68 Ga-DOTATATE uptake (3.8 ± 2.6), but generally lower than that of the normal pituitary gland (6.2 ± 3.2, P < 0.05). In the 11 patients with suspected recurrent pituitary tumors who underwent transsphenoidal adenomectomy, the SUVmax of 18

show abstract

“…To the best of our knowledge, only one case of 68 Ga-DOTATATE uptake in a spinal meningioma has been reported so far. [5] In that case, 68 Ga-DOATATE uptake was noted in a spinal meningioma of a patient suffering from insulinoma. In that case, unspecific uptake of 68 Ga-DOTATATE was observed in a degenerative lesion, which characterizes a potential pitfall in such investigations.…”

Section: Discussionmentioning

confidence: 91%

⁶⁸Ga-DOTATATE-positron emission tomography imaging in spinal meningioma

Slotty

Behrendt

Langen

et al. 2014

J Craniovert Jun Spine

View full text Add to dashboard Cite

Imaging with positron emission tomography (PET) and 68Ga-DOTA peptides is a promising method in intracranial meningiomas. Especially in recurrent meningioma discrimination between scar tissue and recurrent tumor tissue in magnetic resonance imaging (MRI) is often difficult. We report the first case of 68Ga-DOTATATE-PET/computed tomography (PET/CT) imaging in recurrent spinal meningioma. A 64-year-old Caucasian female patient was referred to our department with the second recurrence of thoracic meningothelial meningioma. In MRI, it remained unclear if the multiple enhancements seen represented scar tissue or vital tumor. We offered 68Ga-DOTATATE-PET/CT imaging in order to evaluate the best strategy. 68Ga-DOTATATE-PET/CT imaging revealed strong tracer uptake in parts of the lesions. The pattern did distinctly differ from MRI enhancement. Multiple biopsies were performed in the PET-positive and PET-negative regions. Histological results confirmed the prediction of 68Ga-DOTATATE-PET with vital tumor in PET-positive regions and scar tissue in PET-negative regions. Differentiating scar tissue from tumor can be challenging in recurrent spinal meningioma with MRI alone. In the presented case, 68Ga-DOTATATE-PET imaging was able to differentiate noninvasively between tumor and scar.

show abstract

68Ga DOTATATE PET/CT Uptake in Spinal Lesions and MRI Correlation on a Patient With Neuroendocrine Tumor

Cited by 40 publications

References 6 publications

Principles in the design of ligand-targeted cancer therapeutics and imaging agents

Principles in the design of ligand-targeted cancer therapeutics and imaging agents

PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study

⁶⁸Ga-DOTATATE-positron emission tomography imaging in spinal meningioma

Contact Info

Product

Resources

About

68Ga DOTATATE PET/CT Uptake in Spinal Lesions and MRI Correlation on a Patient With Neuroendocrine Tumor

Cited by 40 publications

References 6 publications

Principles in the design of ligand-targeted cancer therapeutics and imaging agents

Principles in the design of ligand-targeted cancer therapeutics and imaging agents

PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study

68Ga-DOTATATE-positron emission tomography imaging in spinal meningioma

Contact Info

Product

Resources

About

⁶⁸Ga-DOTATATE-positron emission tomography imaging in spinal meningioma